C4 Therapeutics (CCCC)
NASDAQ:CCCC
Top Page
C4 Therapeutics
(NASDAQ:CCCC)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.50
▼(-11.35% Downside)
Action:ReiteratedDate:03/10/26
The score is held down primarily by weak financial performance (persistent losses, cash burn, and 2025 revenue dropping to $0), only partially offset by a stronger balance sheet. Technicals are supportive with an uptrend, but overbought signals temper the near-term setup. Valuation is constrained by unprofitability, while the recent corporate strategy update and stated runway to 2028 provide a meaningful, but secondary, positive catalyst.
Positive Factors
Proprietary platform
C4T's TORPEDO platform targets protein degradation rather than inhibition, a durable scientific differentiation. A modular degrader platform can generate multiple assets across indications, creating potential high-value programs and persistent R&D leverage if clinical biology and target selection remain validated.
Negative Factors
Sustained cash burn
Persistent, large negative operating and free cash flows indicate ongoing cash burn that will continue until commercialization or major partnering payments. Over time this elevates financing and dilution risk, constrains strategic optionality, and forces management to prioritize capital-efficient development or further external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary platform
C4T's TORPEDO platform targets protein degradation rather than inhibition, a durable scientific differentiation. A modular degrader platform can generate multiple assets across indications, creating potential high-value programs and persistent R&D leverage if clinical biology and target selection remain validated.
Read all positive factors
C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$275.17M
Dividend YieldN/A
Average Volume (3M)2.91M
Price to Earnings (P/E)―
Beta (1Y)2.29
Revenue Growth-10.57%
EPS Growth1.98%
CountryUS
Employees110
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding97,578,180
10 Day Avg. Volume1,957,948
30 Day Avg. Volume2,912,468
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue6.09
Enterprise Value/Gross Profit6.41
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$14.67Price Target Upside420.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$21.62M
C4 Therapeutics Business Overview & Revenue Model
Company Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate ...
How the Company Makes Money
null...
C4 Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 35.95M | 35.58M | 20.76M | 31.10M | 45.78M |
| Gross Profit | 27.97M | 35.58M | 13.02M | 31.10M | 45.78M |
| EBITDA | -102.91M | -103.37M | -122.10M | -124.28M | -80.25M |
| Net Income | -104.99M | -105.32M | -132.49M | -128.18M | -83.89M |
Balance Sheet | |||||
| Total Assets | 359.07M | 349.60M | 376.45M | 430.84M | 506.76M |
| Cash, Cash Equivalents and Short-Term Investments | 248.54M | 244.90M | 253.68M | 276.15M | 309.28M |
| Total Debt | 59.98M | 65.76M | 70.98M | 87.15M | 42.88M |
| Total Liabilities | 102.49M | 133.62M | 130.34M | 141.61M | 117.16M |
| Stockholders Equity | 256.59M | 215.99M | 246.11M | 289.23M | 389.61M |
Cash Flow | |||||
| Free Cash Flow | -99.30M | -65.34M | -108.55M | -111.44M | -88.24M |
| Operating Cash Flow | -98.69M | -65.16M | -106.84M | -105.94M | -86.97M |
| Investing Cash Flow | -8.60M | -51.27M | 158.35M | 58.42M | -189.34M |
| Financing Cash Flow | 126.40M | 45.34M | 45.49M | 1.15M | 171.40M |
C4 Therapeutics Technical Analysis
Positive
2.82
Price Trends
2.42
Positive
2.37
Positive
2.34
Positive
Market Momentum
0.02
Positive
55.75
Neutral
75.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 2.82 is above the 20-day moving average (MA) of 2.75, above the 50-day MA of 2.42, and above the 200-day MA of 2.34, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 55.75 is Neutral, neither overbought nor oversold. The STOCH value of 75.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.
C4 Therapeutics Risk Analysis
C4 Therapeutics disclosed 73 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
C4 Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $232.86M | -2.71 | -46.46% | ― | ― | 72.35% | |
52 Neutral | $275.17M | -1.51 | -53.83% | ― | -10.57% | 1.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $741.68M | -18.84 | -63.06% | ― | ― | 59.04% | |
43 Neutral | $88.86M | -2.15 | 13.30% | ― | 448.44% | ― | |
43 Neutral | $18.57M | -2.09 | 389.21% | ― | ― | -234.46% |
* Healthcare Sector Average
CCCC
C4 Therapeutics
2.82
1.49
112.03%
SLS
SELLAS Life Sciences Group
4.13
3.09
297.12%
MCRB
Seres Therapeutics
9.27
-2.18
-19.03%
ELDN
Eledon Pharmaceuticals
3.07
0.24
8.48%
TVGN
Tevogen Bio Holdings
4.46
-47.04
-91.34%
ACTU
Actuate Therapeutics, Inc.
2.48
-4.34
-63.64%
C4 Therapeutics Corporate Events
Business Operations and Strategy
C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy
Positive
Jan 14, 2026
On January 14, 2026, C4 Therapeutics outlined a multi-year strategy centered on advancing its lead IKZF1/3 degrader cemsidomide toward potential best-in-class status in multiple myeloma, alongside a refocused discovery effort on novel targets in v...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.